Agios, changing its identity, to sell cancer drug business to Servier

In a major shift, Agios Pharmaceuticals will sell a portfolio of cancer medicines that it has spent more than half a decade developing to French drugmaker Servier, pivoting to focus on a blood disease treatment and emerging research into rare genetic disorders.